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Abstract—NK cells were found to play an important role in liver ﬁbrosis, a process commonly seen
in a chronic liver disease such as chronic hepatitis C (CHC). The aim of this study was to evaluate
potential differences in relation to coexisting liver steatosis in children with chronic hepatitis C. The
study group consisted of 31 children with chronic hepatitis, aged 7–18 years (mean015±2 years).
Blood samples were taken prior to liver biopsy. The METAVIR scale was used for histological
evaluation. Peripheral lymphocytes were subjected to monoclonal antibodies to CD56 antigen, KIRs
and NKG2D antigens. Cells were assayed by ﬂow cytometry for the ratio of positive cells and mean
ﬂuorescence intensity (MFI). Results were evaluated regarding the presence of liver steatosis. Si-
gniﬁcantly higher mean AST activity as well as higher AST-to-platelets ratio index (APRI) was
observed in a group of children with coexisting liver steatosis. These children had signiﬁcantly
higher MFI for CD158e and lower MFI for NKG2D. All CHC patients had signiﬁcantly higher MFI
for NKG2D than the controls. The proportion of cells with expression of CD158i, KIR2D and APRI
was found independent predictors of liver steatosis in univariate analysis and body mass index in
logistic regression. The expression of NK cell receptors is altered in coexisting steatosis that may
inﬂuence long-term prognosis in CHC.
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INTRODUCTION
Infection with hepatitis C virus (HCV) is still a
signiﬁcant health problem worldwide. HCV is capable of
evading the immune response and causes chronic
infection leading to signiﬁcant consequences such as
liver cirrhosis and hepatocellular carcinoma. Although
the clinical course is relatively mild in childhood, HCV
infection may lead to signiﬁcant lesions in liver
histology that slowly but surely progress with the
duration of infection with a varied rate [1]. Inability of
the host to produce an effective immune response
depends on many factors including innate and acquired
immunity and is particularly important in childhood due
to coexisting immaturity of the immune system.
Natural killer (NK) cells belong to lymphocyte cells
aiming at direct interaction with virus-infected host cells.
Moreover, NK cells secrete cytokines activating T helper
type 1 cells to enhance cytotoxic T cell response. They
also activate dendritic cells [2]. Their multiple functions
are controlled by activating and inhibitory receptors.
Signals from the receptors are integrated to determine
ﬁnal possible activation. NK cells accumulate in the
liver in the state of infection [3]. A recent report shows
many alterations in phenotype, activity and frequency of
NK cells in chronic hepatitis C (CHC) [4].
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Major inhibitory receptors are the killer cells’
immunoglobin-like receptors (KIR) and NKG2A. Key
activating receptors are natural cytotoxicity receptors
that also belong to the KIR family and NKG2D. Most of
the inhibitory receptors recognize MHC class I and
MHC class I-like molecules, while ligands of many
activating receptors remain unknown. NKG2D recog-
nizes ligands induced by cellular stress on virally
infected or transformed cells [5].
Expression of NK cell receptors is altered in
conditions of chronic HCV infection. They may be both
up- and down-regulated in CHC. Recently, lower levels
of NKG2D were described, while expression of KIR
was normal or low [6].
NK cells were found to play an important role in
liver ﬁbrosis, a process commonly seen in chronic liver
disease. NK cells appear to be involved in hepatic
stellate cell (HSC) death; therefore, depletion of NK
cells was leading to the progression of ﬁbrosis on an
animal model [7]. Liver steatosis is a well-known factor
associated with the progression of liver ﬁbrosis and was
found to be an independent predictor of advanced
ﬁbrosis in CHC [8].
Reports regarding the issue in children, with the
additional condition of a developing immune system, are
scarce. The aim of this study was to evaluate potential
differences in relation to coexisting liver steatosis in
children with CHC.
MATERIAL AND METHODS
The study group consisted of 31 children with
CHC—17 boys and 14 girls, aged 7–18 years
(mean015±2 years). The control group included 23
children without liver diseases. Chronic hepatitis C
was diagnosed on the basis of standard clinical
criteria. History data were taken, and all children
underwent clinical examination and abdominal ultra-
sound scanning prior to liver biopsy. Duration of
infection was estimated on the basis of past medical
record counting from the moment of the appearance
of the ﬁrst HCV infection markers. All biopsies were
taken for diagnostic purposes after obtaining in-
formed consent from legal guardians of the patients
according to local legal regulations. Blood samples
were taken at the same time for standard laboratory
tests. HCV-RNA level was measured using RT-PCR–
qualitative test AMPLICOR HCVTM (Roche), ver-
sion 2.0; sensitivity level, 50 IU/ml. The HCV
genotype was established using HCVII Ampliﬁcation
Procedure INNO-LIPA HCV-II, Innogenetics. The
liver biopsy was performed for diagnostic purposes
in all children using the Menghini procedure–Hepaﬁx
kits (needles, 1.4 mm; Braun) in sedation. The
histological evaluation was performed by a patholo-
gist blinded from history and clinical data and
included inﬂammatory activity and ﬁbrosis using the
METAVIR scoring system. On the basis of basic
laboratory parameters, the AST-to-platelets ratio in-
dex (APRI) score was calculated using the following
formula: APRI0(AST level/ULN)/platelet counts
(109/l)×100 [8]. Body mass index (BMI) was
calculated from the formula: body weight (kg)/(body
height (m))2. Characteristics of the study group have
been presented in Table 1.
Flow Cytometry
NK cells were identiﬁed in PBMC as CD3−/
CD56+. NK cell phenotyping was performed using a
blood specimen incubated with the following antibodies
to inhibitory and activating receptors: CD-3—peridinin–
chlorophyll–protein complex (Becton Dickinson),
CD56-allophycocyanin (APC), CD 158b (KIR2DL2/
DL3)-phycoerythrin (PE), CD 158e (KIR3DL1)-PE,
CD158i (KIR2DS4)-PE, KIR2D-PE (Milteneyi Biotec
Inc) and CD314(NKG2D)-PE (R&D Systems). The
following control antibodies were also used: mouse
IgG2a isotype-PE, mouse IgG2a isotype–APC and
mouse IgG2a-PE (Miltenyi Biotec Inc). Red cells were
lysed using FACS lysing solution, and the lymphocytes
were washed three times before further analysis on a
FACS Canto ﬂow cytometer (Becton Dickinson). Re-
sults were presented as the proportion of cells with
expression of a particular receptor as well as mean
ﬂuorescence intensity (MFI). Isotype-matched control
antibodies were used to determine background levels of
staining.
The study obtained approval from the Bioethical
Committee of the University of Medical Sciences in
Poznań, Poland (no. 234/08 from September 4, 2008).
Statistical Analysis
Continuous variables were expressed as mean,
standard deviation, median and range. Normality was
checked using the Shapiro–Wilk test. Consequently,
Mann–Whitney test or Student’s t test was used where
appropriate. Categorical variables were expressed as
frequency and percentage. They were compared by the
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chi-square or Fisher exact test where appropriate.
Comparison of multiple groups was performed using
Kruskal–Wallis test. Correlations were found using
Pearson correlation and Spearman test. Factors associat-
ed with liver steatosis were sought by univariate analysis
and multivariate analysis. Logistic regression was
performed by a model including factors found signiﬁcant
in univariate analysis. Values with p<0.05 or with
conﬁdence interval (CI) not including 1.0 were consid-
ered statistically signiﬁcant.
RESULTS
Mean duration of infection was 11.39±3.68 years
(range, 3–16 years). In the cases of 22 children (71 %),
HCV infection lasted longer than 10 years. The majority
of children were infected by parenteral route (90 %).
Sixty-two percent of children underwent treatment for
childhood malignancy in the past. All of these children
ﬁnished their oncological treatment more than 5 years
prior to the study. Ten children were treated because of
childhood leukaemia with chemotherapy; nine children
had solid tumours and underwent surgical procedures
followed by chemotherapy. None of the children
required bone marrow transplantation. Histological
assessment revealed mild to moderate grading and
staging in the liver (Table 1). Twelve children developed
ﬁbrotic lesions staged F≥2—eight of them were scored
F2, followed by three F3, and one child was scored F4 in
histopathological evaluation. Liver steatosis was present
in biopsy specimens of 12 children. The proportion of
steatosis varied from 0 to 5 %. An example histological
picture of liver steatosis was presented in Fig. 1.
Table 2 displays clinical, laboratory parameters and
APRI in children in relation to liver steatosis. In both
groups, no differences were discovered regarding history
data and the majority of laboratory parameters including:
duration of infection, cholesterol level, HCV-RNA viral
load and viral genotype. Children with liver steatosis had
higher BMI and ALT activity. These results were,
however, not statistically signiﬁcant. Nevertheless, sig-
niﬁcantly higher mean AST activity was observed in this
group of children, as well as higher APRI index. Marked
Table 1. Characteristics of the Study Group—31 Children with CHC
Feature Number Percentage X  SD M Range
Age (years) – – 14.94±2.46 16 2–17
Gender, male/female 17/14 55/45 –
Age at infection (years) – – 3.55±3.30 3 0–12
Duration of infection (years) – – 11.39±3.68 13 3–16
Duration of infection >10 years, Y/N 22/9 71/29
Probable route of infection: nosocomial/vertical 28/2 90/10
Body weight (kg) – – 59.36±14.68 58.00 24–88
Body mass index (kg/m2) – – 20.94±3.79 20.35 12.98–29.41
History of childhood malignancy, Y/N 19/12 61/39 – – –
HCV genotype 1b/1a/3a 7/23/1 23/74/3 – – –
HCV-RNA viral load (IU/ml) – – 1,757,627±3,226,000 367,500 100–14,800,000
ALT (IU/l) – – 71.87±95.55 39 15–486
Inﬂammatory activity (METAVIR) – – 1.41±0.63 1.00 1–3
Fibrosis (METAVIR) – – 1.55±0.87 1.00 1–4
Liver steatosis, Y/N 12/19 39/61 – – –
APRI – – 0.74±0.86 0.44 0.19–3.48
X mean, SD standard deviation, M median, APRI AST-to-platelets ratio index, Y yes, N no
Fig. 1. Chronic hepatitis C with ﬁbrosis forming short ﬁbrous spurs
(stage 2, METAVIR) radiating into the parenchyma from the portal
tract (Sirius red staining). There is also focal fatty change.
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correlations were found between ALT and AST and
proportion of steatosis (r00.38 and r00.39 were
appropriate; p<0.05) and BMI and proportion of
steatosis (r00.55; p<0.05). As far as histological
assessment was concerned, children with coexisting
liver steatosis had slightly higher inﬂammatory activity.
The difference was, however, not statistically signiﬁcant.
Furthermore, inﬂammatory activity correlated to the
proportion of steatosis (r00.38; p<0.05). Both groups
of children did not differ regarding stage of ﬁbrosis and
number of children with ﬁbrosis scored F≥2.
WBC was signiﬁcantly lower in CHC patients
compared to the control group (Table 3). CHC patients
had signiﬁcantly higher MFI of KIR2D than the
controls. Expression of remaining receptors was similar
in both CHC patients and controls. NK cell phenotypes
differed signiﬁcantly in children with CHC in relation to
liver steatosis as presented in Table 4. Although the
number of NK cells was similar in both groups, children
with coexisting liver steatosis had signiﬁcantly higher
mean MFI for CD158e and lower MFI for NKG2D
(Fig. 2a–d). The proportion of cells with the expression
Table 2. Clinical and Laboratory Parameters in Children with CHC with and without Liver Steatosis
Parameter
CHC group with liver steatosis, n012 CHC group without liver steatosis, n019
p valueX±SD X±SD
Age (years) 15.25±1.66 15.00±2.72 0.77
Gender, M/F 5/7 13/6 0.13
Age at infection (years) 3.33±3.42 3.78±3.39 0.72
Duration of infection (years) 11.92±3.23 11.22±4.02 0.62
Duration of infection >10, Y/N 10/2 12/7 0.21
Probable route of infection parenteral/vertical 10/2 18/1 0.29
History of paediatric malignancy, Y/N 5/7 6/13 0.42
Weight (kg) 62.10±14.60 59.33±13.24 0.59
BMI (kg/m2) 22.55±4.52 20.18±2.82 0.08
ALT (IU/l) 114.17±140.98 46.83±33.68 0.06
AST (IU/l) 82.83±74.49 35.28±16.00 0.013*
GGTP (IU/l) 28.08±74.49 40.78±12.41 0.53
PLT (g/l) 237.41±67.41 236±57.24 0.95
Cholesterol (mg/dl) 145.33±35.36 143.72±2.89 0.88
HCV-RNA viral load (IU/ml) 1,672,501±2,813,650 1,814,378±3,552,773 0.90
Genotype 1b/other 4/8 3/16 0.19
Inﬂammatory activity (METAVIR) 1.67±0.78 1.24±0.44 0.067
Fibrosis (METAVIR) 1.75±0.97 1.41±0.80 0.31
Fibrosis score F≥2, Y/N 6/6 13/6 0.25
APRI 1.22±1.25 0.44±0.17 0.013*
APRI AST-to-platelets ratio index, Y yes, N no, X mean, SD standard deviation, M median
*p < .05
Table 3. Expression of Selected Receptors on NK Cells in CHC Patients and in the Control Group
Parameter
Children with CHC n031 Control group n023
p valueX±SD (M) X±SD (M)
WBC (g/l) 6.54±2.30 (6.11) 8.64±2.85 (7.37) 0.0002*
NK cells (cells/μl) 345.49±248.33 (252.16) 340.86±163.73 (376.80) 0.937
CD158b expression—proportion of cells (%) 30.84±11.02 (26.60) 29.87±11.18 (30.60) 0.741
CD158b MFI 3,390.16±1,914.18 (2,921.00) 3,390.16.83±1,542.52 (3,185.00) 0.367
CD158e expression—proportion of cells (%) 14.09±10.82 (10.70) 15.16±13.32 (16.20) 0.732
CD158e MFI 13,575.13±8,873.98 (13,976.00) 9,881.96±8,907.03 (8,454.00) 0.121
KIR2D expression—proportion of cells (%) 47.61±12.28 (46.20) 49.35±13.99 (54.50) 0.059
KIR2D MFI 23,391.82±6,643.03 (21,957.00) 19,040.09±9,720.62 (19,025.00) 0.042*
NKG2D expression—proportion of cells (%) 96.15±4.44 (97.15) 96.70±1.81 (96.75) 0.598
NKG2D MFI 4,627.92±931.47 (4,603.00) 4,827.95±1,402.12 (5,326.50) 0.564
X mean, SD standard deviation, M median
*p < .05
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of these receptors as well as the remaining ones and their
MFI did not differ in both groups of children with CHC.
Example pictures from ﬂow cytometry were presented in
Fig. 3. The proportion of cells expressing CD158i,
Table 4. Expression of Selected Receptors on NK Cells in Both Groups of Children with CHC
Parameter
CHC group with liver steatosis, n012 CHC group without liver steatosis, n019
p valueX±SD (M) X±SD (M)
WBC (g/l) 6.94±1.28 (6.65) 6.16±3.08 (6.51) 0.415
NK cells (cells/μl) 342.48±164.81 (468.04) 322.53±263.90 (293.70) 0.818
CD158b expression—proportion of cells (%) 33.54±8.86 (31.00) 29.35±13.85 (27.65) 0.362
CD158b MFI 3,725.33±2,489.77 (3,295.50) 3,013.83±1,482.11 (2,732.00) 0.334
CD158e expression—proportion of cells (%) 17.55±12.06 (10.60) 11.67±9.09 (14.40) 0.139
CD158e MFI 18,815.92±7,075.30 (17,869.50) 9,656.00±8,087.91 (8,952) 0.003*
KIR2D expression—proportion of cells (%) 53.35±12.28 (50.85) 43.56±13.99 (45.50) 0.059
KIR2D MFI 24,284.00±7,061.97 (21,724.00) 21,813.00±5,171.90 (21,595.00) 0.277
NKG2D expression—proportion of cells (%) 97.86±1.32 (97.15) 94.45±6.59 (96.95) 0.125
NKG2D MFI 4,117.22±360.95 (4,261.00) 5,104.67±1,058.38 (5,321.00) 0.018*
WBC white blood cells, NK natural killer, MFI mean ﬂuorescence intensity, X mean, SD standard deviation, M median
*p < .05
Fig. 2. Mean (a) and median (b) of proportion of cells with expression of selected NK cell receptors and ﬂuorescence intensity (c, d) in children with
chronic hepatitis C with and without liver steatosis.
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KIR2D and NKG2D was inversely related to the age of
patients (r0−0.72, r0−0.68, r0−0.49, were appropriate;
p<0.05). Moreover, MFI of CD158b correlated to the
age at infection (r00.53). Expression of CD158e and
CD158i proportional to aminotransferase activity—ALT
(r00.55 and r00.58, were appropriate, p<0.05) and
AST (r00.53 and r00.55, were appropriate, p<0.05).
MFI of CD 158e was directly related to the proportion of
steatosis (r00.64, p<0.05).
Factors associated with the presence of liver
steatosis were sought using univariate analysis. Presence
of steatosis was not associated with age, age at infection
and duration of infection. In univariate analysis, the
proportions of cells with expression of CD158i, KIR2D,
BMI and APRI were found to be independent predictors
of liver steatosis. The presence of liver steatosis was
more probable with an increase of CD 158i and KIR2D
expression as well as rise in BMI and APRI value.
Moreover, it was more credible with a rise of BMI and
6.62 times more probable with an increase of the APRI
index. Parameters that were found statistically signiﬁcant
in univariate analysis were included in logistic regres-
sion model, and only BMI remained signiﬁcant. An
increase of BMI made liver steatosis 1.43 times more
probable. Results of univariate analysis and logistic
regression were presented in Table 5.
DISCUSSION
Mechanisms underlying liver steatosis in CHC have
been proved to be genotype speciﬁc. Fatty liver is more
commonly related to genotype 3, while genotype 1 was
associated with insulin resistance. HCV affects biosynthe-
sis of fatty acids by enhancing the expression of several
enzymes involved in the process. It also inﬂuences the
assembly and secretion of triglycerides. Moreover, HCV
core protein causes mitochondrial injury and oxidative
stress altering lipid peroxidation [9, 10]. Metabolic
syndrome is seen less frequently in CHC patients
Fig. 3. Flow cytometry diagnostic approach—example pictures for speciﬁc NK cell antibodies.
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compared to non-alcoholic fatty liver disease individuals
[11]. Nevertheless, liver steatosis accelerates the progres-
sion of liver ﬁbrosis in CHC patients [12]. In the current
study, the majority of patients were infected with genotype
1 (all but one patient); therefore, any genotype-related
differences could not be performed. No difference was
observed in the frequency of liver steatosis between
genotype 1b and non-1b infected patients.
As a signiﬁcant proportion of patients were treated for
paediatric malignancy in the past, the study included
patients who had ﬁnished oncological treatment at least
5 years prior to the study to avoid the inﬂuence of
medications used. Thus, steatosis was observedwith similar
frequency among patients with and without oncological
history. Presence of steatosis was associated with higher
AST and APRI level—a non-invasive marker of liver
ﬁbrosis. Since a higher APRI level was described to be
associated with advanced ﬁbrosis [13], a potential link with
increased level of this marker and steatosis (also a predictor
of liver damage) is understandable. Higher ALT activity
and BMI was also seen in the group of children with
steatosis, although the results were not statistically signif-
icant. Thus, both ALTandASTactivities were related to the
proportion of cells with steatosis. Furthermore, existing
reports show that presence of steatosis is related to higher
BMI of patients. Increased fat intake results in accumula-
tion of fatty tissue and a rise in patient weight. Moreover, an
increase in baseline BMI signiﬁcantly reduces the proba-
bility of sustained virological response in paediatric patients
with CHC [14]. In the current study, BMI was found to be a
predictor of steatosis in a logistic regression model.
Although in the current study no difference regarding
liver ﬁbrosis was found between the group of CHC
children with and without coexisting steatosis, further
progression of ﬁbrotic lesions with time may be difﬁcult to
predict. Liver ﬁbrosis is a slow process that may be
aggravated by additional factors, and steatosis is one of
them. Hepatic ﬁbrogenesis has been shown to be affected
by NK cell activation through the release of interferon
gamma (IFN-γ), IFN-α or dsRNA. IFN-γ attenuation of
liver ﬁbrosis occurs also through the direct killing of
activated HSCs [7]. The number of NK cells was found to
be altered in CHC patients leading to lack of control on
HSCs and increased ﬁbrogenesis. Steatosis may also
decrease the number of hepatic NK cells by determining
an alteration in cytokine homeostasis with an ampliﬁed
release of pro-inﬂammatory cytokines. Inverse correlation
between the severity of liver steatosis and NK cell number
in animal models was revealed [15]. In the current study,
however, not the number but the expression of NK cell
receptors was altered. The phenotype of NK cells varied
between CHC patients and controls in terms of higher
KIR2D expression in the ﬁrst group. Moreover, MFI of
CD158e was signiﬁcantly higher, and NKG2D was lower
in CHC children with coexisting steatosis. Thus, the
proportion of cells with expression of CD158e was also
Table 5. Factors Associated with the Presence of Liver Steatosis in Children with CHC
Predictor
Univariate analysis Logistic regression
OR (95 % CI) p OR (95 % CI) p
Age (years) 1.097 (0.78–1.53) 0.56 – –
Age at infection (years) 0.96 (0.76–1.22) 0.77 – –
Duration of infection (years) 1.07 (0.8–1.33) 0.52 –
AST (IU/l) 1.03 (0.99–1.07) 0.09 – –
Expression of CD158b—proportion of cells (%) 1.03 (0.96–1.10) 0.34 – –
CD158b MFI 1.00 (0.99–1.00) 0.92 –
Expression of CD158e—proportion of cells (%) 1.05 (0.97–1.13) 0.19 – –
CD158e MFI 0.99 (0.98–1.00) 0.69 –
Expression of CD158i—proportion of cells (%) 1.04 (0.99–1.08) 0.048* 1.01 (0.93–1.09) 0.81
CD158i MFI 1.11 (0.78–1.12) 0.99 –
Expression of KIR2D—proportion of cells (%) 1.06 (0.99–1.12) 0.049* 1.05 (0.96–1.16) 0.26
KIR2D MFI 1.07 (0.98–1.24) 0.78 –
Expression of NKG2D—proportion of cells (%) 1.31 (0.83–2.05) 0.22 – –
NKG2D MFI 1.00 (0.99–1.01) 0.96 –
Inﬂammatory activity (METAVIR) 3.35 (0.8–13.96) 0.08 – –
Fibrosis (METAVIR) 1.59 (0.62–4.08) 0.304 – –
BMI (kg/m2) 1.23 (0.97–1.56) 0.047* 1.43 (1.01–2.03) 0.04*
APRI [(AST (IU/l)/UNL (IU/l)/PLT (g/l))×100] 6.62 (0.54–80.08) 0.006* 14.8 (0.35–630) 0.14
*p < .05
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higher in CHC children with coexisting liver steatosis, and
the proportion of cells with NKG2D expression did not
differ signiﬁcantly between the groups. MFI reﬂects
intensity of the expression of receptors which is indepen-
dent from the number of cells; therefore, the differences in
MFI may not be reﬂected in the number of cells with the
expression of certain receptors. This phenomenon may
explain lack of signiﬁcance in the proportion of cells
expressing analysed receptors with coexisting signiﬁcant
differences regarding their MFI.
Furthermore, univariate analysis showed a relation
between the presence of ﬁbrosis and other NK cell
receptors—activating CD 158i and inhibitory KIR2D.
Expression of these receptors was also higher in children
with fatty liver in a simple comparison; the difference was,
however, not statistically signiﬁcant. Expression of the
inhibitory CD158e was higher in the presence of steatosis,
while the expression of activating NKG2D was lower in
the same situation. Inhibitory phenotype of NK cells could
be associated with a higher level of liver injury. NK cells
initiate apoptosis of activated HSC or are able to kill them
directly; therefore, their inhibition prevents limitation of
HSC activity. On the other hand, an inhibitory phenotype
of NK cells could result in more advanced liver steatosis.
Lower expression of NKG2D in CHC patients could be
related to the fact that HCV down-regulates a ligand for
this receptor—MHC class I -related chain type A [16].
Furthermore NKG2D expression may be down-regulated
by TGF-beta, a pro-inﬂammatory cytokine released by
Kupffer cells and HSC [17]. Nevertheless, signiﬁcance of
these parameters were not conﬁrmed by univariate
analysis, which revealed that a rise in the proportion of
cells with the expression of activating receptor CD158i and
KIR2D may be related to the presence of liver steatosis.
Thus, logistic regression did not prove these ﬁndings. In
the latter analysis, only BMI of the patients was associated
with liver steatosis.
An inverse relation existed between age of the
patients and the proportion of NK cells expressing
activating receptors CD158i and NKG2D. Moreover,
MFI of inhibitory receptor CD158b was correlated to the
age of CHC children. This phenomenon could explain age-
related differences in the course of CHC. NK cells seem to
display more activating phenotype in the younger age;
therefore, liver injury is at the lower stage in younger
patients. Probably with the duration of infection inhibitory
receptors are expressed in greater extent and therefore NK
cells have smaller potential to inhibit the process of the
liver injury. This ﬁnding, however, requires further studies
on a larger group of children and adults with CHC.
Although not signiﬁcant, children with steatosis had
slightly higher inﬂammatory activity in the Mann–Whitney
test. Inﬂammatory activity was, however, balanced to the
proportion of cells with steatosis. Furthermore, inﬂamma-
tory activity as a predictor of liver steatosis showed
borderline signiﬁcance. In the setting of steatosis, inﬂam-
matory response may be modulated by fatty acids and their
metabolites. Furthermore, activation of immune pathways
can adversely affect hepatic lipid metabolism leading to
liver injury, steatohepatitis and ﬁbrosis. Activation of the
immune system in the condition of steatosis causes
increased hepatic production of TNF-α, Il-12 and IFN-γ,
factors that either activate or stimulate apoptosis of NK
cells. Activation of NK cells results in the inhibition of liver
ﬁbrosis and steatosis down-regulates NK cells. Therefore,
the presence of steatosis may accelerate the progression of
liver ﬁbrosis. On the other hand, intrahepatic NK cell
cytotoxic function is impaired in patients with CHC [4].
The exact intercourse between these processes is probably
more complex than we are currently aware and requires
further studies to elucidate cause–effect relations.
In clinical terms, it has been observed that NK cell
activity is negatively correlatedwith liver ﬁbrosis in patients
with HCV infection. Further studies will be required to
conﬁrm whether stimulating NK cell activity is effective
and safe in treating human liver ﬁbrosis. Moreover,
expression of certain NK cell receptors has been proven to
be related to the results of treatment in CHC [18, 19].
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